Challenges for drug discovery and development in China

References

• Gao CY, Leinfuss E. The evolving landscape of drug development in china. Contract Pharma. 2015. [cited 2016 Sep 29]. Available from http://www.contractpharma.com/issues/2016-05-01/view_features/the-evolving-landscape-of-drug-development-in-China
   Google Scholar
• Wu YL, Zhang H, Yang Y. Cancer drug development in China: recent advances and future challenges. Drug Discov Today. 2015 Jun;20(6):766–771. DOI:10.1016/j.drudis.2014.11.005
   PubMed Web of Science ®Google Scholar
• Xia J, Xu X, Huang P, et al. The potential of CXCL5 as a target for liver cancer - what do we know so far? Expert Opin Ther Targets. 2015 Feb;19(2):141–146. DOI:10.1517/14728222.2014.993317
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhu X, Zhang J. CXCL5 knockdown expression inhibits human bladder cancer T24 cells proliferation and migration. Biochem Biophys Res Commun. 2014 Mar 28;446(1):18–24.
   PubMed Web of Science ®Google Scholar
• Zhu X, Qiao Y, Liu W, et al. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients. Tumour Biol. 2016 Apr;37(4):4569–4577. DOI:10.1007/s13277-015-4275-4
   PubMed Web of Science ®Google Scholar
• Gao Y, Guan Z, Chen J, et al. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9. Int J Oncol. 2015 Aug;47(2):690–700. DOI:10.3892/ijo.2015.3041
   PubMed Web of Science ®Google Scholar
• Lim JB, Chung HW. Serum ENA78/CXCL5, SDF-1/CXCL12, and their combinations as potential biomarkers for prediction of the presence and distant metastasis of primary gastric cancer. Cytokine. 2015 May;73(1):16–22. DOI:10.1016/j.cyto.2015.01.010
   PubMed Web of Science ®Google Scholar
• Zhou SL, Zhou ZJ, Hu ZQ, et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling. Cancer Lett. 2015 Mar 28;358(2):124–135.
   PubMed Web of Science ®Google Scholar
• Hamilton G, Rath B, Klameth L, et al. Small cell lung cancer: recruitment of macrophages by circulating tumor cells. Oncoimmunology. 2015 Oct 29;5(3):e1093277.
   PubMed Web of Science ®Google Scholar
• Echizen K, Hirose O, Maeda Y, et al. Inflammation in gastric cancer: interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. Cancer Sci. 2016 Apr;107(4):391–397. DOI:10.1111/cas.12901
   PubMed Web of Science ®Google Scholar
• Zhuang GF, Tan Y, Yang YZ, et al. Experiment research of cisplatin implants inhibiting transplantation tumor growth and regulating the expression of KLK7 and E-cad of tumor-bearing mice with gastric cancer. Asian Pac J Trop Med. 2016 Jun;9(6):606–609. DOI:10.1016/j.apjtm.2016.04.022
   PubMed Web of Science ®Google Scholar
• Leigh AB, Cheung HP, Lin LZ, et al. Comprehensive and holistic analysis of HT-29 colorectal cancer cells and tumor-bearing nude mouse model: interactions among fractions derived from the Chinese medicine formula tian xian liquid in effects on human colorectal carcinoma. Integr Cancer Ther. 2016;3:1534735416651969.
   Google Scholar
• Shao D, Li J, Zheng X, et al. Janus “nano-bullets” for magnetic targeting liver cancer chemotherapy. Biomaterials. 2016;100:118–133. DOI:10.1016/j.biomaterials.2016.05.030
   PubMed Web of Science ®Google Scholar
• Li Y, Wang P, Chen X, et al. Activation of microbubbles by low-intensity pulsed ultrasound enhances the cytotoxicity of curcumin involving apoptosis induction and cell motility inhibition in human breast cancer MDA-MB-231 cells. Ultrason Sonochem. 2016 Nov;33:26–36. Epub;%2016 Apr 11.:26-36. 10.1016/j.ultsonch.2016.04.012
   PubMed Web of Science ®Google Scholar
• Su Y, Wan D, Song W. Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways. Anticancer Drugs. 2016;27:660–668. DOI:10.1097/CAD.0000000000000381
   PubMed Web of Science ®Google Scholar
• Jin X, Chen L. Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities. Intractable Rare Dis Res. 2015 Feb;4(1):39–48. DOI:10.5582/irdr.2014.01037
   PubMedGoogle Scholar
• Hon KL, Lau CB, Hui PC, et al. Anti-allergic drug discovery in China for eczema: current methods and future strategies. Expert Opin Drug Discov. 2013 Jul;8(7):753–767. DOI:10.1517/17460441.2013.795539
   PubMed Web of Science ®Google Scholar
• Hon KL, Fung CK, Leung AK, et al. Complementary and alternative medicine for childhood asthma: an overview of evidence and patents. Recent Pat Inflamm Allergy Drug Discov. 2015;9(1):66–79.
   PubMedGoogle Scholar
• Hon KL, Fung CK, Leung AK, et al. Recent Patents of Complementary and Alternative Medicine for Allergic Rhinitis. Recent Pat Inflamm Allergy Drug Discov.2015;9:107–119.
   Google Scholar
• Hon KL, Leung AK. Use of Ceramides and Related Products for Childhood-Onset Eczema. Recent Pat Inflamm Allergy Drug Discov. 2013;7:12–19.
   Google Scholar
• Hon KL, Chan BC, Leung PC. Chinese herbal medicine research in eczema treatment. Chinesische Medizin. 2011;6:17.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Yau HC, et al. Paradoxical use of oral and topical steroids in steroid-phobic patients resorting to traditional Chinese medicines. World J Pediatr. 2012 Aug;8(3):263–267. DOI:10.1007/s12519-012-0369-x
   PubMed Web of Science ®Google Scholar
• Zhang S, Zeng X, Wei J, et al. Analysis of trends and opportunities of anti-allergy patents in China from 1998 to 2008. Recent Pat Inflamm Allergy Drug Discov. 2010 Jun;4(2):130–137.
   PubMedGoogle Scholar
• Zhang EQ. Clinical of Traditional Chinese medicine (II). Shanghai China:Publishing House of Shanghai College of Traditional Chinese Medicine; 1990.
   Google Scholar
• Lin X, Tu C, Yang C. [Study on treatment of eczema by Chinese herbal medicine with anti-type IV allergic activity]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000 Apr;20(4):258–260.
   PubMedGoogle Scholar
• Huang TK. A handbook of the composition and pharmacology of common Chinese drugs. Beijing: Chinese Medicine and Technology Press; 1998.
   Google Scholar
• Xu XJ, Banerjee P, Rustin MH, et al. Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczema. Br J Dermatol. 1997 Jan;136(1):54–59.
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Atherton DJ. A controlled trial of traditional Chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol. 1992 Feb;126(2):179–184.
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Atherton DJ. One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol. 1994 Apr;130(4):488–493.
   PubMed Web of Science ®Google Scholar
• Sheehan MP, Stevens H, Ostlere LS, et al. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clinical & Experimental Dermatology. 1995 Mar;20(2):136–140. DOI:10.1111/j.1365-2230.1995.tb02717.x
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2007 Aug;157:357–363. 10.1111/j.1365-2133.2007.07941.x
   PubMed Web of Science ®Google Scholar
• Hon KL, Lo W, Cheng WK, et al. Prospective self-controlled trial of the efficacy and tolerability of a herbal syrup for young children with eczema. J Dermatolog Treat. 2012 Apr;23(2):116–121. DOI:10.3109/09546634.2010.514893
   PubMed Web of Science ®Google Scholar
• Bai YP, Yang DQ, Wang YM. [Clinical study on treatment of acute eczema by Shuangfujin]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Jan;27(1):72–75. Chinese
   PubMedGoogle Scholar
• Kobayashi H. [Clinical evaluation of Hochuekkito in the treatment of atopic dermatitis: a multicenter, double-blind, randomized, placebo-controlled study]. Nihon Yakurigaku Zasshi. 2008 Nov;132(5):285–287. Japanese
   PubMedGoogle Scholar
• Cheng HM, Chiang LC, Jan YM, et al. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol. 2011;155(2):141–148. DOI:10.1159/000318861
   PubMed Web of Science ®Google Scholar
• Fang HS, Ling XM, Gao HY, et al. Jade-Screen Powder Mixture in prevention of recurrent respiratory infections in children. J Tradit Chin Med. 1983 Jun;3(2):137–139.
   PubMedGoogle Scholar
• Han JQ, Zhu YX. [Efficacy and regulation of humoral immunity of jade screen powder as an adjunct therapy in children with asthma]. Zhongguo Dang Dai Er Ke Za Zhi. 2009 Jul;11(7):587–588.
   PubMedGoogle Scholar
• Shen D, Xie X, Zhu Z, et al. Screening active components from Yu-ping-feng-san for regulating initiative key factors in allergic sensitization. PLoS One. 2014 Sep 8;9(9):e107279.
   PubMed Web of Science ®Google Scholar
• Hsu CH, Lu CM, Chang TT. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma. Pediatr Allergy Immunol. 2005 Feb;16(1):76–81. DOI:10.1111/j.1399-3038.2005.00230.x
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Bousquet PJ, Carlsen KH, et al. ARIA update: I–Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006 May;117(5):1054–1062. DOI:10.1016/j.jaci.2005.12.1308
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010 Sep;126(3):466–476. DOI:10.1016/j.jaci.2010.06.047
   PubMed Web of Science ®Google Scholar
• Kern J, Bielory L. Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2014 Dec;14(12):479–0479. DOI:10.1007/s11882-014-0479-8
   PubMed Web of Science ®Google Scholar
• Resnick ES, Bielory BP, Bielory L. Complementary therapy in allergic rhinitis. Curr Allergy Asthma Rep. 2008 Apr;8(2):118–125.
   PubMed Web of Science ®Google Scholar
• Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol. 2009 Feb;123(2):283–286. DOI:10.1016/j.jaci.2008.12.023
   PubMed Web of Science ®Google Scholar
• Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann Allergy Asthma Immunol. 2004 Aug;93(2 Suppl 1):S45–S54.
   PubMed Web of Science ®Google Scholar
• Karkos PD, Leong SC, Arya AK, et al. ‘Complementary ENT’: a systematic review of commonly used supplements. J Laryngol Otol. 2007 Aug;121(8):779–782. DOI:10.1017/S002221510600449X
   PubMed Web of Science ®Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1–43. DOI:10.1177/0194599814561600
   PubMed Web of Science ®Google Scholar
• Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015 Feb;152(2):197–206. DOI:10.1177/0194599814562166
   PubMed Web of Science ®Google Scholar
• Liu CX, Yi XL, Fan HR, et al. Effects of drug transporters on pharmacological responses and safety. Curr Drug Metab. 2015;16(9):732–752.
   PubMed Web of Science ®Google Scholar
• Ai N, Fan X, Ekins S. In silico methods for predicting drug-drug interactions with cytochrome P-450s, transporters and beyond. Adv Drug Deliv Rev. 2015 Jun 23;86. 46–60. Epub;%2015 Mar;%19.:46-60. DOI:10.1016/j.addr.2015.03.006
   PubMed Web of Science ®Google Scholar
• Li L, Tian D, Chen F, et al. Strategies for improving the quantitative bioanalytical performance of LC-MS in pharmacokinetic studies. Curr Drug Metab. 2012 Nov;13(9):1206–1212.
   PubMed Web of Science ®Google Scholar
• Wang X, Ward PA. Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine. J Transl Med. 2012 Nov 7;10: 220. DOI:10.1186/1479-5876-10-220.:220-10.
   PubMed Web of Science ®Google Scholar
• Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today. 2010 Jun;15(11–12):444–450. DOI:10.1016/j.drudis.2010.03.013
   PubMed Web of Science ®Google Scholar
• Yu SS, Feng XZ. [Chemical study on bioactive natural products of novel structural types]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004 Aug;26(4):347–350.
   PubMedGoogle Scholar
• Schuster D, Wolber G. Identification of bioactive natural products by pharmacophore-based virtual screening. Curr Pharm Des. 2010 May;16(15):1666–1681.
   PubMed Web of Science ®Google Scholar
• Genilloud O. Current challenges in the discovery of novel antibacterials from microbial natural products. Recent Pat Antiinfect Drug Discov. 2012 Dec 1; 7(3):189–204.
   PubMedGoogle Scholar
• Henrich CJ, Beutler JA. Matching the power of high throughput screening to the chemical diversity of natural products. Nat Prod Rep. 2013 Oct 11;30(10):1284–1298.
   PubMed Web of Science ®Google Scholar
• Shu WY, Li JL, Wang XD, et al. Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. Acta Pharmacol Sin. 2015 May;36(5):535–543. DOI:10.1038/aps.2015.10
   PubMed Web of Science ®Google Scholar
• Lai Y, Huang M, Li H, et al. Distinct genotype distribution and haplotype profiles in MDR1 gene among Chinese Han, Bai, Wa and Tibetan ethnic groups. Pharmazie. 2012 Nov;67(11):938–941.
   PubMed Web of Science ®Google Scholar
• Shi XJ, Geng F, Jiao Z, et al. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther. 2011 Oct;36(5):614–624. DOI:10.1111/j.1365-2710.2010.01206.x
   PubMed Web of Science ®Google Scholar
• Qiu F, He XJ, Sun YX, et al. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. Pharmacol Rep. 2011;63(3):815–825.
   PubMed Web of Science ®Google Scholar
• Harrer S, Kim SC, Schieber C, et al. Label-free screening of single biomolecules through resistive pulse sensing technology for precision medicine applications. Nanotechnology. 2015 May 8;26(18):182502-4484/26.
   PubMed Web of Science ®Google Scholar
• Simonyan V, Mazumder R. High-Performance Integrated Virtual Environment (HIVE) tools and applications for big data analysis. Genes (Basel). 2014 Sep 30;5(4):957–981.
   PubMed Web of Science ®Google Scholar
• Arjona A, Nuskey B, Rabasseda X, et al. Developments in clinical trials: a Pharma Matters report. Drugs Today (Barc). 2014 Aug;50(8):567–577. DOI:10.1358/dot.2014.50.8.2217229
   PubMed Web of Science ®Google Scholar
• Esposito G, Burgunder JM, Dunlop J, et al. Gene-Tailored treatments for brain disorders: challenges and opportunities. Public Health Genomics. 2016 Jun 1;19(3):170–177.
   PubMed Web of Science ®Google Scholar
• O’Reilly PG, Wen Q, Bankhead P, et al. QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics. BMC Bioinformatics. 2016 May 4;17(1):198–1062.
   PubMed Web of Science ®Google Scholar
• Pennisi M, Russo G, Di S, et al. Computational modeling in melanoma for novel drug discovery. Expert Opin Drug Discov. 2016 Jun;11(6):609–621. DOI:10.1080/17460441.2016.1174688
   PubMed Web of Science ®Google Scholar
• Muller K. Three decades of structure- and property-based molecular design. Chimia (Aarau). 2014;68(7–8):472–482. DOI:10.2533/chimia.2014.472
   PubMed Web of Science ®Google Scholar
• The H-SI. 20th anniversary of proteomics and some of its origins. Proteomics. 2015 Jun;15(11):1773–1776. DOI:10.1002/pmic.201400582
   PubMed Web of Science ®Google Scholar
• Shaw J Why “Big Data” Is a big deal. Information science promises to change the world. Harvard Magazine. [cited 2016 Oct 31] Available from: http://harvardmagazine.com/2014/03/why-big-data-is-a-big-deal
   Google Scholar
• Big Data DV. Predictive analytics in health care. Big Data. 2014 Sep;2(3):113–116. DOI:10.1089/big.2014.1525
   PubMed Web of Science ®Google Scholar
• Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst. 2014 Feb 7;2:3. eCollection;%2014.:3-2. 10.1186/2047-2501-2-3
   PubMedGoogle Scholar
• Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets. Br J Cancer. 2012 Oct 9;107(8):1220–1226.
   PubMed Web of Science ®Google Scholar
• Data-driven healthcare organizations use big data analytics for big gain IBM Software White Paper. [cited 2016 Aug 8]. Available from: http://www03.ibm.com/industries/ca/en/healthcare/documents/Data_driven_healthcare_organizations_use_big_data_analytics_for_big_gains.pdf
   Google Scholar
• iHTT Report, Transforming Health Care Through Big Data Strategies for leveraging big data in the health care industry. [Cited 2016 Oct 31]. Available from: http://c4fd63cb482ce6861463-bc6183f1c18e748a49b87a25911a0555.r93.cf2.rackcdn.com/iHT2_BigData_2013.pdf
   Google Scholar
• Advances in FDA’s Safety Program for Marketed Drugs. Drug safety report. [Cited 2016 Aug 10]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM300946.pdf
   Google Scholar
• Barnes J. Drug safety. Nat Rev Drug Discov. 2007;6:937. DOI:10.1038/nrd2461
   Web of Science ®Google Scholar
• Lee VW, Pang KK, Hui KC, et al. Medication adherence: is it a hidden drug-related problem in hidden elderly? Geriatr Gerontol Int. 2013 Oct;13(4):978–985. DOI:10.1111/ggi.12042
   PubMed Web of Science ®Google Scholar
• Schmidt I, Claesson CB, Westerholm B, et al. The impact of regular multidisciplinary team interventions on psychotropic prescribing in Swedish nursing homes. J Am Geriatr Soc. 1998 Jan;46(1):77–82.
   PubMed Web of Science ®Google Scholar
• Spinewine A, Dhillon S, Mallet L, et al. Implementation of ward-based clinical pharmacy services in Belgium–description of the impact on a geriatric unit. Ann Pharmacother. 2006 Apr;40(4):720–728. DOI:10.1345/aph.1G515
   PubMed Web of Science ®Google Scholar